Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody

Fig. 7

Cured mice are completely protected from A20 lymphoma rechallenge. a, Bioluminescence images of groups, previously treated as indicated, were rechallenged with A20 lymphoma cells. b IFNγ production from purified T cells of all groups(To SV + α4-1BB, 4 months after treatment finished), in the absence or presence of A20 tumor cells (5 × 104 per well), was measured by Elispot assay. c Cytotoxicity assay was performed the same as Fig. 3a. Left 2 panels, total splenocytes were used. Right, purified T cells were used. Left upper, A20 Fluc cells and left lower, CT26 Fluc cells were used for co-culture. d, Significant differential (SD) upregulated gene sets are clustered by DAVID KEGG analysis. *, p < 0.05; **, p < 0.01; ****, p < 0.0001

Back to article page